Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 10.4% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (2.0%)
  • Dividend yield for the last twelve months 2.6%
  • Free cash flow yield 0.5% (LTM)
  • Share price is 9.8% higher than minimum and 35.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (18.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders bought company shares on $2.4 mln (0.002% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+2.2%)90.62
year average price 117.58  


year start price 132.41 2025-06-18

max close price 138.08 2025-06-24

min close price 82.56 2026-05-11

current price 90.62 2026-06-17
Common stocks: 1 746 881 140

Dividend Yield:  2.6%
FCF Yield LTM: 0.5%
EV / LTM EBITDA: 18.1x
EV / EBITDA annualized: 16.4x
Last revenue growth (y/y):  +4.4%
Last growth of EBITDA (y/y):  +16.3%
Historical revenue growth:  +0.9%
Historical growth of EBITDA:  +3.0%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 158 302
Net Debt ($m): 13 587
EV (Enterprise Value): 171 889
EBITDA LTM ($m): 9 487
EV / LTM EBITDA: 18.1x
Price to Book: 3.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-04reuters.com

Abbott recalls glucose sensors after seven deaths linked to faulty readings

2026-02-04247wallst.com

5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends

2026-02-02seekingalpha.com

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

2026-01-31fool.com

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist

2026-01-25seekingalpha.com

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

2026-01-24marketbeat.com

Is Abbott's January Pullback a Good Time to Buy?

2026-01-24seekingalpha.com

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

2026-01-23zacks.com

Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?

2026-01-23forbes.com

Is The Fall In Abbott Stock Justified?

2026-01-23seekingalpha.com

Abbott Laboratories: Buy This Dividend King On Sale Now
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data